This section explores emerging therapeutic strategies focused on both wild-type and mutant forms of p53, with an emphasis on how these interventions modulate immune evasion in hematological malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) (Table 5). The gene discussed is TP53; the disease is acute myeloid leukemia.